• Nick Paul Taylor
• 14 Jun, 2019

BerGenBio has posted updated data from its phase 2 trial of bemcentinib in acute myeloid leukaemia (AML). The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy. The presence of a population of elderly AML patients who are unfit for intensive chemotherapy has been a draw for European biotechs.
Read more...